Rapid clearance of rituximab may contribute to the continued high incidence of autoimmune hematologic complications of chemoimmunotherapy for chronic lymphocytic leukemia by Clifton C. Mo, Ndegwa Njuguna, Paul V. Beum, Margaret A. Lindorfer, Berengere Vire, Elinor Lee, Gerald Marti, Wyndham H Wilson, Ronald P. Taylor, Adrian Wiestner

Get full text

Genome-wide DNA methylation profiling in chronic lymphocytic leukaemia by Qiuyi Zhang, Ying Gao, Ying Gao, Shuchun Lin, Lynn R. Goldin, Yonghong Wang, Holly Stevenson, Daniel C. Edelman, Keith Killian, Gerald Marti, Paul S. Meltzer, Song Xiang, Neil E. Caporaso

Get full text

Towards an FDA-cleared basophil activation test by Oral Alpan, Richard L. Wasserman, Theodore Kim, Amy Darter, Atul Shah, Douglas Jones, Donald McNeil, Henry Li, Laura Ispas, Melinda Rathkopf, Elena Perez, Dareen Siri, Maeve O’Connor, Matthew Plassmeyer, Kimberly Romito, Christina Pettibone, Sean O’Reilly, Søren Ulrik Sønder, Gerald Marti

Get full text

Incidence and risk factors of bleeding-related adverse events in patients with chronic lymphocytic leukemia treated with ibrutinib by Andrew H. Lipsky, Mohammed Z.H. Farooqui, Xin Tian, Sabrina Martyr, Ann M. Cullinane, Khanh Nghiem, Clare Sun, Janet Valdez, Carsten U. Niemann, Sarah E. M. Herman, Nakhle Saba, Susan Soto, Gerald Marti, Gulbu Uzel, Steve M. Holland, Jay N. Lozier, Adrian Wiestner

Get full text